

REMARKS

Sequence Listing

A Response to the Notice to Comply With Requirements for Patent Applications Containing Sequences is being filed concurrently herewith.

Restriction Requirement

Responsive to the Restriction Requirement, Applicants elect the claims of Group I (claims 1-27 and 29, drawn to a composition comprising a polynucleotide encoding an HCV E1E2 complex adsorbed to a cationic microparticle, and a first method of use, for prosecution.

Responsive to the Species Requirement, Applicants make the following species elections:

- (a) poly(-hydroxy acid);
- (b) poly(D,L-lactide-co-glycolide); and
- (c) an oil-in-water emulsion.


Claims 1-27 and 29 are readable on the elected species.

Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 03 June 2009

By: 
Helen Lee
Registration No. 39,270
Telephone: (510) 923-2192
Facsimile: (51) 655-3542

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Corporate Intellectual Property - X100B
P.O. Box 8097
Emeryville, CA 94662-8097